Solvonis Therapeutics (LSE:SVNS) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Solvonis Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Solvonis Therapeutics's long-term debt to total assets ratio declined from Jun. 2023 (0.01) to Jun. 2024 (0.00). It may suggest that Solvonis Therapeutics is progressively becoming less dependent on debt to grow their business.

Solvonis Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Solvonis Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics LT-Debt-to-Total-Asset Chart

Solvonis Therapeutics Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Solvonis Therapeutics Semi-Annual Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					-	-	0.01	0.01	-

Solvonis Therapeutics LT-Debt-to-Total-Asset Calculation

Solvonis Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.022	/	2.434
	=	0.01

Solvonis Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0	/	2.139
	=

Solvonis Therapeutics (LSE:SVNS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Solvonis Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

J4I:Germany

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines